Case Review Form

      * Denotes required field.


      * First Name

      * Last Name

      * Email Address

      * Phone Number

      Cell Phone Number

      Office Phone Number

      Street Address




      Zip Code

      Please provide the best method and times to contact you:

      Date of birth of injured person

      Name of drug:

      Date you started taking the drug (mm-yyyy):

      Date you stopped taking the drug (mm-yyyy):

      Please describe any side effects:

      Other Info:

      No Yes, I agree to the Parker & Waichman LLP disclaimers.Click here to review all.

      Yes, I would like to receive the Parker & Waichman LLP monthly newsletter, InjuryAlert.

      please do not fill out the field below.

Hospira issues recall on painkiller injection due to filling error

Filed May 15th, 2012 Laurie

Pharmaceuticals firm Hospira Inc. has announced a recall on vials of its Hydromorphone injection because some may contain more of the drug than indicated on labels.

According to a recall statement from the firm, the action applies to Hydromorphone Injection, USP, 1 mg/mL (C-II), 1 mL fill in 2.5 mL Carpujectâ„¢, NDC 0409-1283-31. The company has received two complaints of a single Carpujet vial containing more than the indicated 1mL of the drug.

Injections containing too much of a drug, specifically Hydromorphone, can have life-threatening implications for a recipient. Taking too much of this controlled substance opioid painkiller can result in an overdose, cause slowed breathing or stop breathing altogether, a dangerously low blood pressure and heart rate.

The lot affected by the recall was distributed between September and October 2011. The Lot included in the recall is 07547LL. It has an expiration date of July 1, 2013. According to the release, “it was initially distributed to wholesalers and a limited number of hospitals in Alaska, Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Delaware, Florida, Indiana, Louisiana, Maryland, Massachusetts, Minnesota, Missouri, Mississippi, North Carolina, New Hampshire, New Jersey, New York, Ohio, Oklahoma, Oregon, Pennsylvania, Tennessee, Texas, Utah, Washington, and Wisconsin. Hospira is undertaking this recall in consideration of the potential for safety issues if the product is administered to patients.”

There have been no reported adverse reaction reports caused by the defect in the vials which have prompted the recall. Affected product should be quarantined and Hospira should be contacted to retrieve any unused vials.

Be Sociable, Share!

Comments are closed.

Click Here Now, to Have an Attorney Answer Your
Medicinal Drug Injuries Questions
No Cost - No Obligation!